NASDAQ:APLS - Apellis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $74.60
  • Forecasted Upside: 73.45 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$43.01
▲ +1.58 (3.81%)

This chart shows the closing price for APLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Apellis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APLS

Analyst Price Target is $74.60
▲ +73.45% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $74.60, with a high forecast of $130.00 and a low forecast of $28.00. The average price target represents a 73.45% upside from the last price of $43.01.

This chart shows the closing price for APLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 15 investment analysts is to buy stock in Apellis Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/16/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/14/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/13/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/13/2021
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/11/2021
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/9/2021
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/8/2021
  • 1 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$84.00N/A
11/29/2021Roth CapitalReiterated RatingBuy ➝ Neutral$46.00 ➝ $40.00Medium
11/24/2021CitigroupBoost Price TargetBuy$65.00 ➝ $72.00Medium
11/9/2021WedbushLower Price TargetNeutral ➝ Neutral$34.00 ➝ $28.00High
11/9/2021Raymond JamesBoost Price TargetStrong-Buy$102.00 ➝ $116.00High
9/13/2021Robert W. BairdBoost Price TargetOutperform$75.00 ➝ $80.00High
9/12/2021Raymond JamesUpgradeOutperform ➝ Strong-BuyHigh
9/10/2021Robert W. BairdReiterated RatingBuy$75.00High
9/10/2021BMO Capital MarketsLower Price TargetOutperform$89.00 ➝ $69.00High
9/10/2021Needham & Company LLCLower Price TargetBuy$85.00 ➝ $70.00High
9/10/2021Roth CapitalLower Price TargetBuy$80.00 ➝ $46.00High
9/10/2021OppenheimerLower Price TargetOutperform$80.00 ➝ $65.00High
9/10/2021Credit Suisse GroupLower Price TargetNeutral$50.00 ➝ $38.00High
9/10/2021WedbushDowngradeOutperform ➝ Neutral$71.00 ➝ $39.00High
8/19/2021WedbushUpgradeNeutral ➝ OutperformHigh
8/19/2021Jefferies Financial GroupInitiated CoverageBuy$74.00High
8/10/2021Needham & Company LLCReiterated RatingBuy$85.00Medium
8/10/2021Credit Suisse GroupBoost Price TargetNeutral$44.00 ➝ $50.00High
8/10/2021Raymond JamesLower Price TargetStrong-Buy$115.00 ➝ $102.00High
7/19/2021Needham & Company LLCInitiated CoverageBuy$85.00Medium
7/12/2021Needham & Company LLCReiterated RatingBuy$85.00Medium
7/8/2021BMO Capital MarketsBoost Price TargetOutperform$68.00 ➝ $89.00High
7/2/2021JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$91.00 ➝ $101.00Low
7/1/2021CowenBoost Price TargetOutperform$60.00 ➝ $70.00High
6/28/2021Needham & Company LLCBoost Price TargetBuy$65.00 ➝ $85.00Medium
5/20/2021UBS GroupInitiated CoverageBuy$82.00Low
5/18/2021BMO Capital MarketsBoost Price TargetOutperform$64.00 ➝ $68.00High
5/18/2021OppenheimerBoost Price TargetOutperform ➝ Outperform$64.00 ➝ $67.00Medium
5/17/2021Raymond JamesBoost Price TargetStrong-Buy$104.00 ➝ $115.00Medium
5/17/2021Roth CapitalBoost Price TargetBuy$69.00 ➝ $80.00High
4/29/2021Credit Suisse GroupBoost Price TargetNeutral$37.00 ➝ $39.00High
4/16/2021The Goldman Sachs GroupInitiated CoverageBuy$130.00Medium
2/26/2021Credit Suisse GroupBoost Price TargetNeutral$35.00 ➝ $37.00High
1/29/2021Credit Suisse GroupBoost Price TargetNeutral$31.00 ➝ $35.00High
1/8/2021Raymond JamesBoost Price TargetStrong-Buy$78.00 ➝ $104.00Low
12/15/2020Roth CapitalBoost Price TargetBuy$50.00 ➝ $73.00Low
12/10/2020CowenBoost Price TargetOutperform$45.00 ➝ $55.00Medium
12/4/2020JPMorgan Chase & Co.Boost Price Target$50.00 ➝ $875.00Medium
12/1/2020BMO Capital MarketsBoost Price TargetOutperform$57.00 ➝ $66.00Low
11/23/2020Smith Barney CitigroupBoost Price Target$53.00 ➝ $67.00Low
11/19/2020Needham & Company LLCInitiated CoverageBuy$59.00Low
10/9/2020Cantor FitzgeraldReiterated RatingOverweightLow
8/31/2020Stifel NicolausInitiated CoverageBuy$40.00High
7/20/2020Roth CapitalInitiated CoverageBuy$50.00High
6/30/2020CitigroupLower Price TargetBuy$56.00 ➝ $54.00High
6/16/2020BTIG ResearchInitiated CoverageNeutralHigh
6/12/2020OppenheimerReiterated RatingBuy$62.00High
6/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$54.00 ➝ $56.00High
5/28/2020UBS GroupInitiated CoverageAddMedium
4/28/2020Cantor FitzgeraldBoost Price TargetOverweight$54.00 ➝ $61.00High
3/31/2020Raymond JamesInitiated CoverageStrong-Buy$86.00High
3/31/2020BMO Capital MarketsInitiated CoverageOutperform$54.00High
3/11/2020WedbushUpgradeUnderperform ➝ Neutral$29.00High
3/2/2020Credit Suisse GroupLower Price TargetNeutral$36.00 ➝ $34.00High
2/28/2020CowenReiterated RatingBuy$40.00High
1/7/2020Cantor FitzgeraldReiterated RatingBuy$54.00High
1/7/2020OppenheimerBoost Price TargetBuy$52.00 ➝ $62.00High
1/7/2020CitigroupBoost Price Target$37.00 ➝ $80.00High
1/7/2020CowenReiterated RatingBuy$40.00High
1/7/2020SVB LeerinkInitiated CoverageMarket Perform$30.00High
1/7/2020Robert W. BairdReiterated RatingOutperform ➝ Overweight$45.00 ➝ $70.00High
12/19/2019Bank of AmericaInitiated CoverageBuy$36.00High
11/27/2019WedbushInitiated CoverageUnderperform$23.00N/A
11/25/2019Cantor FitzgeraldReiterated RatingOverweight$50.00 ➝ $54.00Medium
11/21/2019WedbushInitiated CoverageUnderperform$23.00High
11/5/2019Credit Suisse GroupInitiated CoverageNeutral$33.00Medium
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
8/1/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$52.00 ➝ $50.00Low
7/31/2019CowenSet Price TargetBuy$40.00Medium
7/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$35.00 ➝ $49.00High
7/9/2019OppenheimerInitiated CoverageOutperform$52.00 ➝ $52.00High
6/16/2019CowenReiterated RatingBuy$40.00High
5/8/2019Cantor FitzgeraldReiterated RatingBuy$52.00Medium
3/28/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$45.00Low
2/28/2019Cantor FitzgeraldSet Price TargetBuy$57.00High
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$34.00High
1/8/2019B. RileyInitiated CoverageBuy$40.00Low
12/20/2018Cantor FitzgeraldReiterated RatingBuy$53.00High
12/6/2018CitigroupBoost Price TargetBuy$34.00 ➝ $40.00Medium
12/3/2018Cantor FitzgeraldSet Price TargetBuy$53.00High
11/14/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$38.00 ➝ $34.00High
11/12/2018Cantor FitzgeraldSet Price TargetBuy$53.00Low
10/1/2018Cantor FitzgeraldSet Price TargetBuy$53.00Low
9/13/2018B. RileyBoost Price TargetBuy$27.00 ➝ $40.00Low
9/4/2018Cantor FitzgeraldSet Price TargetBuy$53.00High
8/7/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Buy$52.00 ➝ $53.00Medium
8/1/2018CowenReiterated RatingBuy$40.00Medium
7/31/2018Cantor FitzgeraldSet Price TargetBuy$52.00High
7/30/2018B. RileyUpgradeNeutral ➝ Buy$27.00High
7/10/2018CowenInitiated CoverageOutperform$40.00Low
6/27/2018Cantor FitzgeraldReiterated RatingBuy$52.00High
6/7/2018Cantor FitzgeraldSet Price TargetBuy$52.00Low
5/23/2018Cantor FitzgeraldInitiated CoverageOverweightLow
4/12/2018B. RileyDowngradeBuy ➝ Neutral$27.00High
3/23/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $35.00Low
2/8/2018B. RileyInitiated CoverageBuy ➝ Buy$27.00Low
12/4/2017Evercore ISIInitiated CoverageOutperformHigh
12/4/2017CitigroupInitiated CoverageBuy$23.00High
12/4/2017JPMorgan Chase & Co.Initiated CoverageOverweight$31.00High
(Data available from 12/8/2016 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/10/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/9/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/9/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/8/2021
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/8/2021

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $43.01
Low: $40.92
High: $43.22

50 Day Range

MA: $37.08
Low: $30.74
High: $47.11

52 Week Range

Now: $43.01
Low: $27.50
High: $73.00

Volume

858,428 shs

Average Volume

1,061,316 shs

Market Capitalization

$3.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Apellis Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Apellis Pharmaceuticals in the last year: BMO Capital Markets, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Roth Capital, The Goldman Sachs Group, Inc., UBS Group AG, and Wedbush.
View the latest analyst ratings for APLS.

What is the current price target for Apellis Pharmaceuticals?

14 Wall Street analysts have set twelve-month price targets for Apellis Pharmaceuticals in the last year. Their average twelve-month price target is $73.93, suggesting a possible upside of 78.4%. The Goldman Sachs Group, Inc. has the highest price target set, predicting APLS will reach $130.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $28.00 for Apellis Pharmaceuticals in the next year.
View the latest price targets for APLS.

What is the current consensus analyst rating for Apellis Pharmaceuticals?

Apellis Pharmaceuticals currently has 3 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APLS will outperform the market and that investors should add to their positions of Apellis Pharmaceuticals.
View the latest ratings for APLS.

How do I contact Apellis Pharmaceuticals' investor relations team?

Apellis Pharmaceuticals' physical mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company's listed phone number is (617) 977-5700 and its investor relations email address is [email protected] The official website for Apellis Pharmaceuticals is www.apellis.com.